GlassScriptPhysician profile
Fallon Wortham
NPI 1346010899
$2,265.12
in general payments reported to CMS, 2019-2025
15 companies · $562 in 2025
The $562 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $203 · 2024: $1,501 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,105 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,104.79 |
| Education | $160.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $563.73 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $317.06 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $283.17 | 2024-2025 | |
| Tris Pharma INC | $276.69 | 2024-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Alkermes, INC. | $190.87 | 2023-2024 | Aristada, Aristada Initio, Lybalvi |
| Axsome Therapeutics, INC. | $177.41 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.71 | 2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $102.22 | 2023-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $73.80 | 2024 | |
| Janssen Pharmaceuticals, INC | $64.40 | 2023-2025 | Invega Sustenna, Spravato |
| Corium, LLC | $31.88 | 2024-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $26.10 | 2025 | Fanapt |
| Janssen Biotech, INC. | $20.41 | 2023 | |
| Idorsia Pharmaceuticals US INC | $19.59 | 2024 | Quviviq |
| Vertical Pharmaceuticals, LLC | $13.08 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fallon Wortham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.